肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

WCLC 2019：评估脂质体伊立替康（ONIVYDE）作为小细胞肺癌的二线疗法

2019-09-09 allan MedSci原创

Onivyde脂质体伊立替康WCLC
关注

Ipsen和Servier近日宣布，评估脂质体伊立替康（ONIVYDE）在小细胞肺癌（SCLC）患者中初步安全性和有效性的II/III期研究已经取得初步结果。这些结果将在2019年世界肺癌大会上报告。

Ipsen和Servier近日宣布，评估脂质体伊立替康（ONIVYDE）在小细胞肺癌（SCLC）患者中初步安全性和有效性的II/III期研究已经取得初步结果。这些结果将在2019年世界肺癌大会上报告。

RESILIENT（NCT03088813）试验是一项随机、开放标签的II/III期研究，旨在评估研究性脂质体伊立替康作为SCLC患者单药疗法的安全性、耐受性和有效性，这些患者在一线铂类治疗后出现疾病进展。II期研究包括剂量递增分析，以确定在满足安全性和耐受性前提下的适当剂量。III期研究将重点关注有效性，包括无进展生存期（PFS）和总生存期（OS）。


原始出处：

http://www.firstwordpharma.com/node/1664680#axzz5yvEPt24Y

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1976461, encodeId=fe4519e6461f5, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Mar 08 10:56:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036815, encodeId=e1862036815e2, content=<a href='/topic/show?id=54f81338108' target=_blank style='color:#2F92EE;'>#Onivyde#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13381, encryptionId=54f81338108, topicName=Onivyde)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Wed Oct 23 06:56:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007909, encodeId=5336200e90902, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Apr 23 23:56:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299406, encodeId=63281299406fd, content=<a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂质体伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84426, encryptionId=2b7f8442613, topicName=脂质体伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412368, encodeId=b787141236808, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372493, encodeId=dc0b3e249369, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 09 13:02:11 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2020-03-08 shizhenshan

    #脂质体#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1976461, encodeId=fe4519e6461f5, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Mar 08 10:56:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036815, encodeId=e1862036815e2, content=<a href='/topic/show?id=54f81338108' target=_blank style='color:#2F92EE;'>#Onivyde#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13381, encryptionId=54f81338108, topicName=Onivyde)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Wed Oct 23 06:56:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007909, encodeId=5336200e90902, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Apr 23 23:56:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299406, encodeId=63281299406fd, content=<a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂质体伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84426, encryptionId=2b7f8442613, topicName=脂质体伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412368, encodeId=b787141236808, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372493, encodeId=dc0b3e249369, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 09 13:02:11 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2019-10-23 longerg

    #Onivyde#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1976461, encodeId=fe4519e6461f5, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Mar 08 10:56:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036815, encodeId=e1862036815e2, content=<a href='/topic/show?id=54f81338108' target=_blank style='color:#2F92EE;'>#Onivyde#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13381, encryptionId=54f81338108, topicName=Onivyde)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Wed Oct 23 06:56:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007909, encodeId=5336200e90902, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Apr 23 23:56:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299406, encodeId=63281299406fd, content=<a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂质体伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84426, encryptionId=2b7f8442613, topicName=脂质体伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412368, encodeId=b787141236808, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372493, encodeId=dc0b3e249369, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 09 13:02:11 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2020-04-23 tamgche

    #NIV#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1976461, encodeId=fe4519e6461f5, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Mar 08 10:56:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036815, encodeId=e1862036815e2, content=<a href='/topic/show?id=54f81338108' target=_blank style='color:#2F92EE;'>#Onivyde#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13381, encryptionId=54f81338108, topicName=Onivyde)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Wed Oct 23 06:56:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007909, encodeId=5336200e90902, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Apr 23 23:56:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299406, encodeId=63281299406fd, content=<a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂质体伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84426, encryptionId=2b7f8442613, topicName=脂质体伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412368, encodeId=b787141236808, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372493, encodeId=dc0b3e249369, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 09 13:02:11 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2019-09-10 shalley66

    #脂质体伊立替康#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1976461, encodeId=fe4519e6461f5, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Mar 08 10:56:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036815, encodeId=e1862036815e2, content=<a href='/topic/show?id=54f81338108' target=_blank style='color:#2F92EE;'>#Onivyde#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13381, encryptionId=54f81338108, topicName=Onivyde)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Wed Oct 23 06:56:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007909, encodeId=5336200e90902, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Apr 23 23:56:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299406, encodeId=63281299406fd, content=<a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂质体伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84426, encryptionId=2b7f8442613, topicName=脂质体伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412368, encodeId=b787141236808, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372493, encodeId=dc0b3e249369, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 09 13:02:11 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2019-09-10 木头人514

    #WCLC#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1976461, encodeId=fe4519e6461f5, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Mar 08 10:56:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036815, encodeId=e1862036815e2, content=<a href='/topic/show?id=54f81338108' target=_blank style='color:#2F92EE;'>#Onivyde#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13381, encryptionId=54f81338108, topicName=Onivyde)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Wed Oct 23 06:56:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007909, encodeId=5336200e90902, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Apr 23 23:56:00 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299406, encodeId=63281299406fd, content=<a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂质体伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84426, encryptionId=2b7f8442613, topicName=脂质体伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412368, encodeId=b787141236808, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Tue Sep 10 23:56:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372493, encodeId=dc0b3e249369, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 09 13:02:11 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2019-09-09 1ddf0692m34(暂无匿称)

    学习了，谢谢分享

    0

相关资讯

Shire胰腺癌药物Onivyde惨遭英国NICE拒绝！

英国制药公司Shire的胰腺癌药物Onivyde近日在英国监管方面遭受挫折。英国NICE发布最终指南，拒绝将Onivyde用于英国国家服务系统（NHS）用于胰腺癌患者的治疗。具体而言，NICE拒绝批准Onivyde联合5-氟尿嘧啶（5-FU）及亚叶酸（LV）用于吉西他滨方案治疗后病情进展的转移性胰腺癌患者。在美国和欧盟，Oniv